ALAMEDA, Calif., Aug. 10, 2009 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) a biopharmaceutical company, today reported financial results for its second quarter ended June 30, 2009. At June 30, 2009, Avigen had approximately $41.6 million in financial assets, including cash, cash equivalents and available-for-sale securities and restricted investments, compared with approximately $56.8 million at December 31, 2008 before repaying $7.0 million of outstanding bank borrowings in March 2009. More complete financial results are detailed in the financial tables below.
